CND Life Sciences Achieves Major FDA Breakthrough Designation
CND Life Sciences, Inc. (CND) is excited to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for its innovative Syn-One Test. This advancement is pivotal for clinicians diagnosing synucleinopathies in older patients who present with specific neurologic conditions.
Understanding the Breakthrough Device Designation
The FDA's Breakthrough Devices Program accelerates the development and review process for medical devices that show promise in providing more effective treatment or diagnostics for serious conditions. For a device to qualify for this designation, it must meet certain criteria. This includes demonstrating a reasonable expectation that it could significantly improve therapy or diagnosis for life-threatening conditions or providing benefits that surpass available alternatives.
The Significance of the Syn-One Test
The Syn-One Test identifies abnormal phosphorylated alpha-synuclein (P-SYN) proteins. By relying on samples taken from minimally invasive skin biopsies, this test is designed to support doctors in diagnosing serious neurodegenerative diseases. The test utilizes three small skin samples from specific areas to assess nerve structure and provide valuable diagnostic insights.
CNN Life Sciences and Its Impact on Healthcare
Since its inception, CND Life Sciences has innovated within the medical technology space, aiding healthcare providers with advanced diagnostic tools for neurodegenerative diseases. With just a simple skin biopsy, Syn-One offers hope to both doctors and patients in terms of earlier and more accurate diagnosis of conditions such as Parkinson's disease.
Expanding Clinical Applications
CND introduced the Syn-One Test as a laboratory developed test (LDT) several years ago. Since then, nearly 50,000 patients across various clinical settings have benefitted from its use, representing a significant milestone in neurodiagnostics. The broad adoption speaks volumes about the confidence physicians have in this test when making diagnostic decisions.
Success Stories and Research Publications
The importance of Syn-One has been affirmed through substantial clinical research, including a major study published in a prominent medical journal revealing remarkable sensitivity in detecting abnormal synuclein. Recent industry collaborations have further underlined the test's clinical utility, indicating that it can effectively adjust patient diagnoses based on retrospective chart reviews.
Looking Forward: Future Developments
As CND Life Sciences moves forward with the Breakthrough Device Designation, the company is committed to enhancing the capabilities of the Syn-One Test. The aim is to work closely with the FDA and facilitate its potential to revolutionize how clinicians approach neurodegenerative disorders.
The Vision of CND Life Sciences
The dedicated team at CND Life Sciences, led by experienced professionals, understands the complexities involved in diagnosing neurodegenerative diseases. Their ongoing commitment emphasizes not only development but providing clinicians with necessary tools to improve patient outcomes.
About CND Life Sciences
CND Life Sciences focuses on developing cutting-edge diagnostic solutions for patients at risk for neurodegenerative conditions. Through scientific innovation and collaboration with leading healthcare professionals, the company aims to facilitate timely and accurate diagnoses. With its CLIA-certified lab, CND is committed to maintaining high standards in medical testing and patient care.
Frequently Asked Questions
What is the Syn-One Test?
The Syn-One Test is a laboratory developed test aimed at diagnosing synucleinopathies using small skin biopsy samples to detect specific proteins associated with neurodegenerative diseases.
Who can benefit from the Syn-One Test?
Patients aged 40 and older displaying clinical features suggestive of synucleinopathy can benefit from the Syn-One Test.
What does the FDA Breakthrough Device Designation mean?
It signifies that the Syn-One Test has met specific criteria promising enhanced treatment or diagnostic solutions for serious health conditions, expediting its development and review process.
How has the test performed in clinical settings?
Studies have demonstrated over 95% sensitivity in detecting abnormal synuclein, proving its effectiveness across multiple patient scenarios.
Is CND Life Sciences expanding its research?
Yes, CND is actively pursuing further research opportunities and collaborations to improve and expand the application of the Syn-One Test in diagnosing neurodegenerative diseases.
